Cidara Therapeutics Regains Compliance With Nasdaq Continued Listing Rules
Cidara Therapeutics Regains Compliance With Nasdaq Continued Listing Rules
SAN DIEGO, May 15, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff (the Staff) of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with Nasdaq's requirements for continued listing. In addition, the Nasdaq Hearing Panel (the Panel) imposed a discretionary Panel monitor until May 14, 2025, such that if the Company fails to maintain compliance with any continued listing requirement during such period, the Staff will issue a delist determination letter and the Company will promptly schedule a new hearing before the Panel to address such noncompliance.
聖地亞哥，2024年5月15日——使用其專有Cloudbreak的生物技術公司Cidara Therapeutics, Inc.（納斯達克股票代碼：CDTX） 開發藥物-FC偶聯物（DFC）免疫療法的平台今天宣佈，它於2024年5月14日收到了納斯達克股票市場有限責任公司（納斯達克）上市資格部門工作人員（員工）的來信，通知該公司已恢復遵守納斯達克繼續上市的要求。此外，納斯達克聽證小組（以下簡稱 “小組”）規定小組在2025年5月14日之前進行全權監督，因此，如果公司在此期間未能遵守任何持續上市要求，工作人員將發出除名決定書，公司將立即安排該小組舉行新的聽證會，以解決此類違規行爲。
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create "single molecule cocktails" comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
關於 Cidara Therapeu
Cidara Therapeutics 正在使用其專有的 Cloudb 開發新型藥物-FC偶聯物（DFC）的平台。這些靶向免疫療法爲創建 “單分子混合物” 提供了獨特的機會，該混合物由靶向小分子和與人類抗體片段（Fc）耦合的肽組成。DFC旨在通過抑制特定疾病靶標的同時激活免疫系統來挽救生命並提高面臨嚴重疾病的患者的護理標準。Cidara 總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問 www.cidara.com。
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
投資者聯繫人：
布萊恩·裏奇
生命科學顧問
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
媒體聯繫人：
邁克爾·菲茨休
LifeSci
mfitzhugh@lifescicomms.com
譯文內容由第三人軟體翻譯。